Having Trouble Quitting Smoking? Cigarettes With Low Nicotine Levels Could Be The Solution

Updated Jan 15, 2025 | 09:01 AM IST

SummaryNicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.
Low-nicotine level of cigarettes

Cigarettes with ultralow nicotine levels are now being called the game-changer in the fight against smoking. If you are having trouble in quitting smoking, then, it is for you, that soon the Biden White House is expected to formally propose a plan that will order cigarette nicotine levels to be reduced, reports The Washington Post. For now though, it has been a failure, as these cigarettes, also known as VLN cigarettes that stands for very low nicotine are only available in 5,100 stores in 26 states. This is a very small fraction of the overall market for cigarettes. The company that makes it, 22nd Century, is struggling not because of the low supply, but also from the advocates who have long believed slashing nicotine levels altogether.

The Advent and ideation

Nicotine is a chemical that is produced naturally from tobacco that makes the cigarette and also keeps people hooked. While it is believed that it makes people alert, and get the "hit" to keep them going, it exposes the users to harmful substances, carcinogens, and increases the risk of heart disease, lung cancer, and other illness.

Ultralow-nicotine cigarettes, like the VLN brand, contain about 95% less nicotine than the regular cigarettes. The idea is quite simple: without the addictive grip of nicotine, smokers will find it easier to quit. Research too has shown some promise. For instance, the studies funded by the National Institute on Drug Abuse revealed that very low nicotine cigarettes reduced addiction potential significantly without having users to increase their smoking frequency. However, the problem is, why would anyone choose for a low-nicotine that does not make them feel the same way, when the high-nicotine cigarette is right next to it, making them feel the same way, with the same alertness, sold at the same price.

“It’s very hard to imagine someone actively choosing to continue to use a low-nicotine product for the same price when a high-nicotine product is right next to it,” said Eric Donny, a Wake Forest University School of Medicine nicotine researcher.

No wonder, the experiment with low nicotine product by Philip Morris' Next cigarettes in the 1980s and Vector Tobacco's Quest brand in the early 2000s, flopped.

FDA's Role in the Push

The Food and Drug Administration (FDA) has supported the development of such products, even allowing VLN cigarettes to be marketed as lower-risk options. However, these products remain a niche market, available in only a fraction of U.S. stores.

Recently, the Biden administration has considered a bold step—mandating a dramatic reduction in nicotine levels for all cigarettes sold in the United States. Supporters believe this move could save millions of lives, while critics, including tobacco companies, warn of potential unintended consequences.

What Could Be The Challenges?

Resistance from Big Tobacco Companies: They could argue that slashing nicotine levels could backfire. Their claim is, smokers will turn to black markets or smoke more to satisfy their cravings, which may lead to greater exposure to harmful substances.

Consumer Reluctance: History is proof to the instances of smokers being hesitant to embrace the low-nicotine products.

Political Hurdle: It may face political roadblocks, as under the Trump administration, plans to cut nicotine were shelved.

Could Low-Nicotine Cigarettes Be The Solution?

Advocates believe that ultralow-nicotine cigarettes could be a game-changer, comparing them to decaf coffee or non-alcoholic beer—products that reduce harm while offering a similar experience.

Some experts warn that a black market for traditional cigarettes could undermine these efforts. They also stress the need for safer alternatives, such as vaping products, to support smokers transitioning away from traditional cigarettes.

End of Article

New Pancreatic Cancer Drug Daxaronrasib May Benefit Patients With Lung And Ovarian Tumors Too

Updated Jun 1, 2026 | 10:46 AM IST

Summary​In a clinical trial, daxaronrasib demonstrated a median overall survival of 13.2 months, compared with 6.7 months for standard chemotherapy.
New Pancreatic Cancer Drug Daxaronrasib May Benefit Patients With Lung And Ovarian Cancers Too

Credit: iStock/Reuters

Developed by the US-based late-stage clinical oncology company Revolution Medicines, daxaronrasib has shown promise in improving survival rates among patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

In a clinical trial, daxaronrasib demonstrated a median overall survival of 13.2 months, compared with 6.7 months for standard chemotherapy.

Experts believe the drug may also prove effective against other cancers, including cancerous tumors in lung and ovaries.

The drug works by targeting mutations in the KRAS gene, which are found across multiple cancer types, including lung, colorectal, ovarian, endometrial and a type of bile duct cancer known as cholangiocarcinoma.

“Daxaronrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy,” said Brian M. Wolpin, professor of medicine at Harvard Medical School and principal investigator of the trial.

“Pancreas cancer may be the first for this drug, but there will be others,” he added, noting that “Now the floodgates open.”

What Is Daxaronrasib? How Does It Work?

Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer

Daxaronrasib is a daily oral pill that has demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.

Described as a multi-selective inhibitor of RAS(ON) proteins, it is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.

The drug works by blocking KRAS signalling proteins that drive tumor growth.

“It’s been incredibly hard to drug that mutation,” Wolpin said, NBC News reported. “That mutated protein is like a round ball, and you just can’t get the drug to stick to it, to block the effect.” It’s only “through some really amazing chemistry work,” he said, that scientists have been able to develop a drug to work on the mutation.

Daraxonrasib is that first drug. It works by pairing up with a protein called cyclophilin A inside cells, acting like a “molecular glue,” Wolpin said, glomming onto the mutated protein.

Pancreatic cancer is considered one of the most RAS-dependent cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations. Similar RAS-targeting drugs are also being developed for pancreatic, lung and colon cancers.

“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.

The findings was presented at a plenary session of the American Society of Clinical Oncology’s meeting in Chicago on May 31, and simultaneously published in the New England Journal of Medicine.

Read More: Ozempic-Style Drugs May Slowdown Cancer, Study Finds

What Are The Side Effects?

According to the company, “Daxaronrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.”

Previous studies have shown that rash is the most common side effect. Other frequently reported adverse effects include:

  • Mouth sores
  • Diarrhoea
  • Nausea
  • Vomiting

FDA Fast-Tracks Daxaronrasib

Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.

Revolution Medicines said it plans to submit the data to global regulators, including the U.S. Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.

End of Article

Mann Ki Baat: PM Modi Addresses The Heatwave, Suggests Aam Panna, Sattu Sherbet

Updated Jun 1, 2026 | 11:31 AM IST

SummaryIn the monthly radio broadcast, Maan Ki Baat, Prime Minister Narendra Modi has urged the people to take precautions during the scorching summer heat.
Mann Ki Baat: PM Modi Addresses The Heatwave, Suggests Suitable Drinks

Credit: Canva

Prime Minister Narendra Modi once again addressed the nation through his monthly radio broadcast, Maan Ki Baat. It was the 134th installment of the broadcast, and the Prime Minister urged the people of India to take extra precautions in summer's scorching heat.

The Prime Minister said, "It is very hot in most parts of the country right now. Strong sun, hot winds, it is very important to take care of yourself in such weather. Keep drinking water. If at all you have to go out in the sun, do so with caution." He added, "Don't forget the guidelines issued by various government departments in this regard."

Then the Prime Minister also addressed traditional food and drinking practices in different parts of the country to stay fit even during the hot summer. He urged the citizens to drink regional traditional drinks to stay hydrated and named popular options like Aam Panna, Sattu sherbet, Kokum sherbet, Sol Kadhi, Panakam, Neer Mor, Sambaram, Bael Pana, and Buttermilk. "Ek Bharat Shreshtha Bharat," he added.

The Prime Minister also mentions mangoes, which are a household summer treat in India. He said, "Every region… its own mango, its own flavor, its own aroma." Then he described these different mangoes and their specialties as well.

Prime Minister Narendra Modi also mentions the journey of the Indian mangoes from domestic production to the global market.

Easy Tips To Stay Fit During a Heatwave

Drink water consistently at regular intervals instead of gulping large quantities at once. Electrolyte-rich fluids like coconut water, lemon water with a pinch of salt, or buttermilk are healthy, affordable options to soothe parched throats.

Add items like curd, rice, cucumber, and bottle gourd to your diet and avoid red meat and fried foods during peak summer days.

Extreme temperatures put additional stress on the cardiovascular system, especially in people with hypertension, diabetes, or heart conditions. Make sure to take all prescribed medications exactly as advised—don’t skip doses even if you experience heat-induced nausea. If you feel dizzy or experience palpitations or severe fatigue, consult your doctor as soon as possible.

Air conditioning is helpful, but overexposure can lead to dry skin, headaches, and respiratory discomfort. Once every two or three hours, step away from your desk for a few minutes. Walk or stand, and sip some water.

End of Article

Brazil Starts Investigation On Possible Ebola Infection, 37-Year-Old Is In São Paulo Hospital

Updated May 31, 2026 | 02:00 PM IST

SummaryThe health authorities in Brazil are investigating a 37-year-old Ebola suspect in São Paulo. The person is from the Democratic Republic of Congo.
Brazil Starts Investigation On Possible Ebola Infection, 37-Year-Old Is In São Paulo Hospital

Credit: iStock

The whole world is in terror of Ebola spreading, and countries are on alert. Recently, there has been a possible Ebola-infected person under investigation by the health authorities of Brazil. As per the media reports, the suspected 37-year-old man is admitted to the hospital in São Paulo.

The person with possible Ebola infection is from the Democratic Republic of Congo and started to show Ebola-like symptoms after returning from the African country.

The local health authorities have ensured that he is in isolation, and the hospital specializes in the care of suspected or confirmed cases of the disease.

What Is Ebola?

Ebola is a severe and, in most cases, deadly disease caused by viruses predominantly found in Africa. The spread of the disease happens through contact with infected body fluids.

Some symptoms can indicate a possible infection. This includes fever, weakness, headache, muscle pain, vomiting, diarrhea, sore throat, and unexplained bleeding. This eventually leads to severe complications like bleeding, organ failure, and death. The hosts of the virus are animals like bats, primates, and antelopes.

Why Ebola Spread Is Not Like COVID

The virus is raising serious global health concerns, with Tedros Adhanom Ghebreyesus, WHO Director General, stating that the ongoing Ebola outbreak "is spreading rapidly" and "outpacing us". Yet experts say that it is not COVID and cannot spread like it.

“Ebola does NOT spread through casual airborne exposure like influenza or COVID-19. Individuals become infectious only after symptoms begin, not during the incubation period. The incubation period ranges from 2 to 21 days,” said Dr. Ishwar Gilada, Secretary General, People’s Health Organisation (India).

Experts further explained that Ebola is far more difficult to spread than airborne respiratory viruses such as influenza, COVID-19, measles, and even the Andes strain of hantavirus, which recently caused an outbreak on a cruise ship.

It is because Ebola is not airborne. Ebola does not spread through coughing, sneezing, or casual contact like shaking hands. It spreads only via body fluid contact.

In addition, people with Ebola also do not spread the virus before developing symptoms. This means that during Ebola’s incubation period, which ranges from 2–21 days, an infected person is generally not contagious, unlike COVID-19, where transmission can occur before symptoms appear.

End of Article